Big Change To Netincome vs End Period Cash Flow Analysis

PRM Stock

CAD 13.30 0.18 1.37%

Big Pharma financial indicator trend analysis is way more than just evaluating Big Pharma Split prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Big Pharma Split is a good investment. Please check the relationship between Big Pharma Change To Netincome and its End Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Big Pharma Split. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Change To Netincome vs End Period Cash Flow

Change To Netincome vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Big Pharma Split Change To Netincome account and End Period Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Big Pharma's Change To Netincome and End Period Cash Flow is -0.92. Overlapping area represents the amount of variation of Change To Netincome that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Big Pharma Split, assuming nothing else is changed. The correlation between historical values of Big Pharma's Change To Netincome and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Netincome of Big Pharma Split are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Change To Netincome i.e., Big Pharma's Change To Netincome and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Change To Netincome

End Period Cash Flow

Most indicators from Big Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Big Pharma Split current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Big Pharma Split. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 1st of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.13, while Selling General Administrative is likely to drop about 308.6 K.

	2021	2022	2023	2024 (projected)
Gross Profit	5.4M	3.7M	311.8K	296.2K
Total Revenue	5.4M	3.7M	311.8K	296.2K

Gross Profit Total Revenue

Big Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Long Term Investments	Total Current Assets	Net Working Capital	Short Term Debt
Total Assets		0.39	-0.1	-0.11	0.75	0.45	-0.46	0.34	0.57	0.35	0.42	-0.53	-0.02	0.03	0.47	0.61	0.4	-0.3	0.4	-0.28	0.36	0.02	0.48	0.15	0.17	0.39
Short Long Term Debt Total	0.39		0.49	0.54	0.78	0.04	-0.97	0.96	-0.27	0.83	0.96	-0.9	-0.67	0.69	-0.38	0.6	0.96	-0.4	0.18	-0.72	0.18	0.55	0.95	0.64	0.79	1.0
Other Current Liab	-0.1	0.49		0.88	0.13	-0.44	-0.45	0.4	-0.66	0.55	0.34	-0.27	-0.98	0.97	-0.33	0.42	0.37	-0.74	-0.59	-0.81	0.62	0.45	0.27	0.95	0.82	0.49
Total Current Liabilities	-0.11	0.54	0.88		0.14	-0.08	-0.53	0.48	-0.64	0.51	0.43	-0.4	-0.89	0.88	-0.5	0.38	0.45	-0.63	-0.33	-0.65	0.59	0.18	0.39	0.82	0.68	0.54
Total Stockholder Equity	0.75	0.78	0.13	0.14		0.39	-0.71	0.76	0.25	0.64	0.83	-0.76	-0.31	0.34	0.21	0.82	0.81	-0.27	0.42	-0.4	0.3	0.54	0.81	0.41	0.5	0.78
Net Tangible Assets	0.45	0.04	-0.44	-0.08	0.39		-0.06	0.08	0.5	-0.08	0.17	-0.2	0.36	-0.36	0.32	0.34	0.12	0.16	0.71	0.43	0.2	-0.34	0.23	-0.3	-0.35	0.04
Current Deferred Revenue	-0.46	-0.97	-0.45	-0.53	-0.71	-0.06		-0.9	0.25	-0.81	-0.9	0.91	0.62	-0.64	0.4	-0.53	-0.89	0.46	-0.19	0.76	-0.18	-0.38	-0.94	-0.58	-0.75	-0.97
Net Debt	0.34	0.96	0.4	0.48	0.76	0.08	-0.9		-0.12	0.63	0.99	-0.93	-0.58	0.6	-0.42	0.52	0.99	-0.24	0.12	-0.58	0.08	0.53	0.97	0.53	0.69	0.96
Accounts Payable	0.57	-0.27	-0.66	-0.64	0.25	0.5	0.25	-0.12		-0.51	-0.05	-0.05	0.62	-0.62	0.56	0.02	-0.06	0.39	0.28	0.49	-0.14	-0.28	-0.04	-0.53	-0.53	-0.27
Cash	0.35	0.83	0.55	0.51	0.64	-0.08	-0.81	0.63	-0.51		0.65	-0.58	-0.67	0.69	-0.17	0.65	0.64	-0.59	0.23	-0.77	0.36	0.54	0.66	0.7	0.79	0.83
Non Current Assets Total	0.42	0.96	0.34	0.43	0.83	0.17	-0.9	0.99	-0.05	0.65		-0.95	-0.54	0.56	-0.35	0.56	1.0	-0.21	0.22	-0.54	0.09	0.51	0.97	0.5	0.65	0.96
Non Currrent Assets Other	-0.53	-0.9	-0.27	-0.4	-0.76	-0.2	0.91	-0.93	-0.05	-0.58	-0.95		0.47	-0.48	0.41	-0.43	-0.95	0.17	-0.26	0.53	-0.04	-0.25	-0.94	-0.41	-0.53	-0.9
Other Assets	-0.02	-0.67	-0.98	-0.89	-0.31	0.36	0.62	-0.58	0.62	-0.67	-0.54	0.47		-1.0	0.38	-0.51	-0.56	0.72	0.46	0.86	-0.58	-0.51	-0.47	-0.97	-0.89	-0.67
Cash And Short Term Investments	0.03	0.69	0.97	0.88	0.34	-0.36	-0.64	0.6	-0.62	0.69	0.56	-0.48	-1.0		-0.38	0.52	0.58	-0.71	-0.44	-0.87	0.56	0.53	0.49	0.97	0.9	0.69
Net Receivables	0.47	-0.38	-0.33	-0.5	0.21	0.32	0.4	-0.42	0.56	-0.17	-0.35	0.41	0.38	-0.38		0.42	-0.37	-0.17	0.12	0.25	0.4	0.1	-0.31	-0.16	-0.21	-0.38
Common Stock Shares Outstanding	0.61	0.6	0.42	0.38	0.82	0.34	-0.53	0.52	0.02	0.65	0.56	-0.43	-0.51	0.52	0.42		0.55	-0.66	0.14	-0.5	0.76	0.59	0.56	0.66	0.65	0.6
Short Term Investments	0.4	0.96	0.37	0.45	0.81	0.12	-0.89	0.99	-0.06	0.64	1.0	-0.95	-0.56	0.58	-0.37	0.55		-0.22	0.17	-0.56	0.09	0.53	0.96	0.53	0.67	0.96
Non Current Liabilities Total	-0.3	-0.4	-0.74	-0.63	-0.27	0.16	0.46	-0.24	0.39	-0.59	-0.21	0.17	0.72	-0.71	-0.17	-0.66	-0.22		0.38	0.81	-0.82	-0.34	-0.28	-0.8	-0.78	-0.4
Other Current Assets	0.4	0.18	-0.59	-0.33	0.42	0.71	-0.19	0.12	0.28	0.23	0.22	-0.26	0.46	-0.44	0.12	0.14	0.17	0.38		0.36	-0.24	-0.2	0.27	-0.43	-0.34	0.18
Other Stockholder Equity	-0.28	-0.72	-0.81	-0.65	-0.4	0.43	0.76	-0.58	0.49	-0.77	-0.54	0.53	0.86	-0.87	0.25	-0.5	-0.56	0.81	0.36		-0.46	-0.48	-0.56	-0.87	-0.93	-0.72
Total Liab	0.36	0.18	0.62	0.59	0.3	0.2	-0.18	0.08	-0.14	0.36	0.09	-0.04	-0.58	0.56	0.4	0.76	0.09	-0.82	-0.24	-0.46		0.2	0.09	0.7	0.49	0.18
Net Invested Capital	0.02	0.55	0.45	0.18	0.54	-0.34	-0.38	0.53	-0.28	0.54	0.51	-0.25	-0.51	0.53	0.1	0.59	0.53	-0.34	-0.2	-0.48	0.2		0.44	0.58	0.72	0.55
Long Term Investments	0.48	0.95	0.27	0.39	0.81	0.23	-0.94	0.97	-0.04	0.66	0.97	-0.94	-0.47	0.49	-0.31	0.56	0.96	-0.28	0.27	-0.56	0.09	0.44		0.44	0.64	0.95
Total Current Assets	0.15	0.64	0.95	0.82	0.41	-0.3	-0.58	0.53	-0.53	0.7	0.5	-0.41	-0.97	0.97	-0.16	0.66	0.53	-0.8	-0.43	-0.87	0.7	0.58	0.44		0.91	0.64
Net Working Capital	0.17	0.79	0.82	0.68	0.5	-0.35	-0.75	0.69	-0.53	0.79	0.65	-0.53	-0.89	0.9	-0.21	0.65	0.67	-0.78	-0.34	-0.93	0.49	0.72	0.64	0.91		0.79
Short Term Debt	0.39	1.0	0.49	0.54	0.78	0.04	-0.97	0.96	-0.27	0.83	0.96	-0.9	-0.67	0.69	-0.38	0.6	0.96	-0.4	0.18	-0.72	0.18	0.55	0.95	0.64	0.79

Click cells to compare fundamentals

Big Pharma Account Relationship Matchups

Big Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.2M	22.9M	37.8M	39.1M	26.5M	34.5M
Short Long Term Debt Total	10.6M	9.3M	14.9M	9.9M	10.3M	9.4M
Other Current Liab	43.9K	(9.7M)	(15.2M)	(10.2M)	(10.5M)	(10.0M)
Total Current Liabilities	10.9M	213.2K	339.0K	347.8K	11.1M	5.9M
Total Stockholder Equity	16.3M	13.2M	22.4M	19.7M	15.9M	14.3M
Net Tangible Assets	18.8M	16.3M	13.2M	22.4M	25.8M	19.7M
Net Debt	10.0M	9.1M	13.4M	9.0M	10.1M	8.7M
Accounts Payable	241.4K	213.2K	339.0K	347.8K	248.7K	299.6K
Cash	536.1K	231.0K	1.4M	819.2K	204.2K	194.0K
Non Current Assets Total	26.3M	22.4M	36.1M	24.3M	26.3M	22.8M
Non Currrent Assets Other	(26.3M)	(22.4M)	(36.1M)	(24.3M)	(26.3M)	(27.6M)
Other Assets	(33.1M)	(26.3M)	151.1K	(718.2K)	(826.0K)	(867.3K)
Cash And Short Term Investments	26.9M	231.0K	1.4M	819.2K	204.2K	194.0K
Net Receivables	73.1K	104.3K	102.6K	14.0M	77.1K	73.3K
Common Stock Shares Outstanding	1.2M	995.8K	1.3M	1.5M	1.2M	1.0M
Short Term Investments	26.3M	22.4M	35.3M	23.7M	25.5M	22.5M
Liabilities And Stockholders Equity	27.2M	22.9M	37.8M	39.1M	26.5M	34.5M
Non Current Liabilities Total	10.9M	9.7M	15.4M	347.8K	10.7M	7.5M
Other Current Assets	235.8K	194.5K	964.1K	545.1K	718.2K	488.0K
Total Liab	10.9M	213.2K	339.0K	19.4M	10.7M	8.0M
Total Current Assets	27.2M	335.2K	1.5M	14.8M	999.5K	949.6K
Short Term Debt	10.6M	9.3M	14.9M	9.9M	10.3M	9.4M
Common Stock	16.3M	13.2M	22.4M	19.7M	15.9M	14.3M

Pair Trading with Big Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Big Stock

0.75	AEMC	Alaska Energy Metals	Pair Corr
0.71	CMC	Cielo Waste Solutions	Pair Corr

Moving against Big Stock

0.95	LQWD	LQwD FinTech Corp	Pair Corr
0.66	ERC	Eros Resources Corp	Pair Corr

The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.

The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Big Stock

Balance Sheet is a snapshot of the financial position of Big Pharma Split at a specified time, usually calculated after every quarter, six months, or one year. Big Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Big Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Big currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Big Change To Netincome vs End Period Cash Flow Analysis

Change To Netincome vs End Period Cash Flow

Change To Netincome vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Change To Netincome

End Period Cash Flow

Big Pharma fundamental ratios Correlations

Big Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Big Pharma fundamental ratios Accounts

Pair Trading with Big Pharma

Moving together with Big Stock

Moving against Big Stock

Other Information on Investing in Big Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Short Term Investments	+ 1.0	Non Current Assets Total
Non Current Assets Total	+ 0.99	Net Debt
Short Term Investments	+ 0.99	Net Debt
Cash And Short Term Investments	+ 0.97	Other Current Liab
Long Term Investments	+ 0.97	Net Debt

Cash And Short Term Investments	- 1.0	Other Assets
Other Assets	- 0.98	Other Current Liab
Total Current Assets	- 0.97	Other Assets
Short Term Debt	- 0.97	Current Deferred Revenue
Current Deferred Revenue	- 0.97	Short Long Term Debt Total
Short Term Investments	- 0.95	Non Currrent Assets Other